VCAM1 and metabolic dysfunction-associated steatotic liver disease: In the present study, we repurposed the anti-VCAM-1 nanobody-based tracer 99mTc-cAbVCAM1-5 (originally developed for the detection of inflammatory atherosclerotic lesions20,25) to non-invasively evaluate liver inflammation in preclinical models of NAFLD.